Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005090 · ClinicalTrials.gov registry record · Phase 3
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT00005090 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 11 participants.
The verdict
NCT00005090, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without peripheral stem cell transplantation in treating Hodgkin's Disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without peripheral stem cell transplantation in treating men who have stage III or stage IV Hodgkin's disease.
Interventions
- DRUG cyclophosphamide
- DRUG carmustine
- DRUG dacarbazine
- DRUG doxorubicin hydrochloride
- BIOLOGICAL bleomycin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2000-04 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005090
The ClinicalTrials.gov registry entry for NCT00005090 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005090 about?
NCT00005090 is a clinical study titled "S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known if c...
What is the current status of trial NCT00005090?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2000-04. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00005090?
The interventions under investigation include: cyclophosphamide (DRUG), carmustine (DRUG), dacarbazine (DRUG), doxorubicin hydrochloride (DRUG), bleomycin sulfate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005090?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.